Study to Determine Skin Irritation and/or Sensitization Potential of an Antifungal Cream Containing Trolamine (Repeated Insult Patch Test)

Hypersensitivity Clinical Trial

Official title:

HT201321- Repeated Insult Patch Test With Modified Challenge

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04531540
• Other study ID #: 18156
• Status: Completed
• Phase: Phase 3
• Start date: September 9, 2013
• Est. completion date: October 18, 2013

Study information

• Verified date: October 2020
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this study researcher want to learn more about possible skin reactions such after repeated application of an antifungal cream containing Trolamine. They are especially interested in skin irritations or allergic skin reactions. The study plans to enroll about 225 female or male participants with the age 18 - 79 years. The antifungal test cream will be applied on the back between the shoulder blades of the participants and covered by a special dressing patch. This will be repeated 3 times a week for the first 3 weeks of this study applying the cream on the same area of the back. At each visit the skin will be investigated for redness, dryness and other reactions. After a rest period of two weeks the test cream will be applied on the same skin area as before and on a second new skin area nearby. After 2 and 4 days the two skin areas will again be investigated for redness, dryness and other reactions.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 225
• Est. completion date: October 18, 2013
• Est. primary completion date: October 18, 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 79 Years

Eligibility

Inclusion Criteria:

• Subjects must have been aged 18 to 79 years, inclusive;

• Female subjects must have produced a negative urine pregnancy test prior to the initiation and also at the completion of the trial;

• Subjects must have been capable of understanding and following directions.

Exclusion Criteria:

• Subjects who were in ill health or taking medication, other than birth control, which could influence the purpose, integrity or outcome of the trial;

• Subjects who had any visible skin disease that might be confused with a skin reaction to the test material;

• Subjects who were participating in another clinical trial at this facility or any other facility;

• Subjects who used topical or systemic steroids or antihistamines for at least 7 days prior to trial initiation and during the duration of the trial;

• Subjects who had a history of adverse reactions to adhesive tape, cosmetics, OTC drugs or other personal care products;

• Subjects judged by the PI to be inappropriate for the trial;

• Female subjects who were pregnant as evidenced by a urine pregnancy test, planning to become pregnant, or nursing during the course of the trial.

Related Conditions & MeSH terms

• Hypersensitivity

Intervention

Drug:
• Butenafine HCl 1% (BAY1896425)
Approximately 0.2 g of cream containing butenafine HCl 1% were applied to the upper back skin.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Irritation Response Evaluation According to Erythema Scoring Scale During Induction Phase - All Enrolled Subjects	Prior to each patch application and after the last patch removal, the test sites were evaluated for gross changes according to the Erythema Scoring Scale: score 0=No visible erythema; score 0.5=Slight, barely perceptible erythema; score 1=Mild erythema; score 2=Moderate erythema; score 3=Marked erythema; score 4=Severe erythema.	After 4 weeks
Primary	Allergic Reaction Evaluation According to Erythema Scoring Scale During Challenge Phase - All Enrolled Subjects	Prior to each patch application and after the last patch removal, the test sites were evaluated for gross changes according to the Erythema Scoring Scale: score 0=No visible erythema; score 0.5=Slight, barely perceptible erythema; score 1=Mild erythema; score 2=Moderate erythema; score 3=Marked erythema; score 4=Severe erythema.	After 6 weeks
Primary	Irritation Response Evaluation According to Erythema Scoring Scale During Induction Phase - All Evaluable Subjects	Prior to each patch application and after the last patch removal, the test sites were evaluated for gross changes according to the Erythema Scoring Scale: score 0=No visible erythema; score 0.5=Slight, barely perceptible erythema; score 1=Mild erythema; score 2=Moderate erythema; score 3=Marked erythema; score 4=Severe erythema.	After 4 weeks
Primary	Allergic Reaction Evaluation According to Erythema Scoring Scale During Challenge Phase - All Evaluable Subjects	Prior to each patch application and after the last patch removal, the test sites were evaluated for gross changes according to the Erythema Scoring Scale: score 0=No visible erythema; score 0.5=Slight, barely perceptible erythema; score 1=Mild erythema; score 2=Moderate erythema; score 3=Marked erythema; score 4=Severe erythema.	After 6 weeks

External Links

•   Click here to find results for studies related to Bayer Healthcare products.